Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma

NCT01526135 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

493

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)

Interventions

DRUG: mFolfirinox
DRUG: Gemcitabine

Sponsor

UNICANCER

Collaborators

[object Object]